Stacey A McCaffrey, PhD, Ryan A Black, PhD, Albert J Villapiano, EdD, Robert N Jamison, PhD, Stephen F Butler, PhD Pain Medicine, pnx311, https://doi.org/10.1093/pm/pnx311 Published: 11 December 2017 Abstract Objective The Current Opioid Misuse Measure (COMM) is a commonly used self-report instrument to identify and monitor aberrant opioid-related behavior in chronic pain patients on opioid therapy. However, the length… Read more »
FOR IMMEDIATE RELEASE Inflexxion, Inc. appoints Dr. Jody Green to Chief Scientific Officer WALTHAM, MA (November 30, 2017) – Inflexxion, Inc. announced the appointment of Jody Green, PhD as Chief Scientific Officer, effective November 27. Green brings to Inflexxion a strong background and experience in the drug safety and opioid abuse space. She will lead… Read more »
For ASI-MV, BHI-MV, and CHAT customers – Join us on Wednesday, December 14 2017 from 1 pm to 2 pm EST for our webinar titled “Monthly Enhanced Training: ASI-MV & BHI-MV – Bridging data into treatment planning.” This training will include: – Gain an understanding of how to use the ASI-MV & BHI-MV data for… Read more »
See our latest infographic below on the power behind the ASI-MV network. To learn more, visit our behavioral health product suite page.
Taryn Dailey-Govoni, Jared Beaumont, Theresa Cassidy Inflexxion, Inc., Waltham, MA, USA Presented at PAINWeek 2017 Read our poster for “Profiling non-medical use of tapentadol products among recreational drug abusers” here Abstract Purpose Prescription opioid misuse and abuse is a public health epidemic in the United States (ONDCP 2015) and a growing source of morbidity, mortality,… Read more »
Last week the President’s Commission on Combatting Drug Addiction and the Opioid Crisis released its final report, which included a list of 56 recommendations for addressing the many challenges this epidemic imposes on America. The goal of these recommendations, as stated by the Commission, is “to combat the opioid crisis and drug addiction in our… Read more »
Click here to read our latest article, The Power of an Electronic Clinical Assessment for Pain and Opioid Misuse Risk: Leveraging SOAPP & COMM in a Digital Era
Inflexxion is speaking at the 4th Human Abuse Liability & Abuse-Deterrent Formulations Summit from November 6-7 in Bethesda, MD at the Hyatt Regency Bethesda. The following is an abstract for our presentation titled: “ADF Effectiveness: Making the case to payers and clinicians” which will be presented by Theresa Cassidy, Vice President of Scientific Research & Strategy, Inflexxion: Although… Read more »
Inflexxion will be hosting a webinar titled, “Improve your Assessment Process with Self-Administered Behavioral Health Solutions,” on Wednesday, October 12 at 1:00 pm EST. Join us for this informative session to learn how to streamline the assessment process for your clients using the ASI-MV and BHI-MV evidence-based tools. These client self-administered behavioral health solutions gather data… Read more »
Inflexxion, Inc. announced today that Allscripts has certified PainCAS™ as part of the Allscripts Developer Program. PainCAS enables Allscripts ambulatory EHR users to assess pain, functioning, and risk of problematic opioid-related behaviors in patients with chronic pain. Developed in part with support from the National Institutes of Health (NIH), grants (Grant No. R44DA026359, PI S.F. Butler and Grant No. R44DA015617, PI S.F. Butler), PainCAS is a scientifically validated web-based, patient self-report clinical tool for assessing pain and opioid misuse risk in patients with chronic pain.